



PEX PharmaSequence monthly report - February 2020

Total open market (sell-out report)

	February 2020	Change in comparison to			Cumulative YTD		Forecast		
		January 2020	January 2020	February 2019	2020	Change vs 2019	2020	Change vs 2019	Change vs 2018
Total turnover (PLN million)									
Total open market ¹	3 348	-2.2%	-2.2%	9.7%	6 771	6.5%	38 607	3.9%	11.6%
Rx reimbursed ²	1 060	-4.4%	-4.4%	4.2%	2 168	3.4%	12 953	2.3%	6.4%
Rx nonreimbursed ³	744	-3.3%	-3.3%	13.1%	1 512	11.1%	8 750	5.3%	16.5%
Non Rx products ⁴	1 522	0.3%	0.3%	12.2%	3 039	6.6%	16 563	4.0%	13.2%
Reimbursement									
Reimbursement value (PLN million)	794	-4.8%	-4.8%	5.1%	1 627	4.7%	9 861	3.8%	10.4%
Reimbursement share in total turnover	23.7%	-2.6%	-2.6%	-4.2%	24.0%	-0.5%	25.5%	0.0%	-1.1%
Reimbursement share in reimbursed sales	73.8%	-0.1%	-0.1%	0.8%	73.8%	1.6%	74.7%	1.0%	3.1%
Average price per pack (PLN)									
Total ¹	22.0	0.3%	0.3%	4.9%	21.3	1.8%	22.1	4.1%	6.1%
For reimbursed Rx products ²	29.2	2.3%	2.3%	3.0%	29.2	3.9%	29.3	1.7%	4.6%
For nonreimbursed Rx products ³	27.6	1.1%	1.1%	6.0%	27.6	6.7%	28.3	5.3%	11.5%
For Non Rx products ⁴	17.2	0.1%	0.1%	6.4%	17.2	5.8%	17.6	3.1%	11.5%
Average mark-up									
Total ¹	25.1%	1.5%	1.5%	0.9%	24.9%	0.3%	24.4%	-1.3%	-2.6%
For reimbursed Rx products ²	19.1%	1.7%	1.7%	4.5%	18.9%	1.1%	19.0%	-1.0%	1.8%
For nonreimbursed Rx products ³	22.0%	5.6%	5.6%	10.0%	21.4%	5.0%	20.4%	-3.5%	-10.7%
For Non Rx products ⁴	29.3%	0.8%	0.8%	-5.2%	29.2%	-2.1%	27.5%	-5.2%	-6.7%
Average pharmacy									
Number of patients in pharmacies	4 310	-1.1%	-1.1%	10.8%	8 670	7.2%	47 533	1.8%	8.5%
Total turnover (PLN thousand) ¹	243	-1.6%	-1.6%	15.4%	490	12.1%	2 822	7.8%	21.6%

- Total pharmacy turnover cumulative in PLN million -

2020	Pharmacy market total ¹		Rx reimbursed prescriptions ²		Rx nonreimbursed prescriptions ³		Non Rx products ⁴	
	Total	Change vs 2019	Total	Change vs 2019	Total	Change vs 2019	Total	Change vs 2019
January	3 423	3.5%	1 108	2.7%	769	9.2%	1 517	1.5%
February	6 771	6.5%	2 168	3.4%	1 512	11.1%	3 039	6.6%
March								
April								
May								
June								
July								
August								
September								
October								
November								
December								

Retail sales in PLN

PEX PharmaSequence Sp. z o.o.,
ul. Kłobucka 23, 02-699 Warszawa
tel. 022-886-47-15, fax. 022-638-21-29
e-mail: biuro@pexps.pl
<http://www.pexps.pl>

Sąd Rejonowy dla m. st. Warszawy w Warszawie, XIII Wydział Gospodarczy,
KRS 0000178089, REGON: 015579675, NIP 9512093564, kapitał zakładowy 1 000 000 zł.




Retail sales in PLN


PEX PharmaSequence monthly report - February 2020

Trends

- Total monthly pharmacy sales in PLN million -



- Total monthly sales in an average pharmacy in PLN -



Retail sales in PLN

PEX PharmaSequence Sp. z o.o.,
 ul. Kłobucka 23, 02-699 Warszawa
 tel. 022-886-47-15, fax. 022-638-21-29
 e-mail: biuro@pexps.pl
<http://www.pexps.pl>

Sąd Rejonowy dla m. st. Warszawy w Warszawie, XIII Wydział Gospodarczy,
 KRS 0000178089, REGON: 015579675, NIP 9512093564, kapitał zakładowy 1 000 000 zł



PEX PharmaSequence monthly report - February 2020


average pharmacy

	February'20	YTD'2020	January'20	Change		February'19	Change		YTD'2019	Change	
				Value	%		Value	%		Value	%
Total turnover (thousand PLN)											
Total open market ¹	243	490	247	-4.0	-1.6%	211	32.5	15.4%	437	53.0	12.1%
Rx reimbursed ²	77	157	80	-3.0	-3.8%	70	6.7	9.6%	144	12.8	8.9%
Rx nonreimbursed ³	54	109	55	-1.5	-2.7%	45	8.6	19.0%	94	15.9	17.0%
Non Rx products ⁴	110	220	109	1.0	0.9%	94	16.9	18.1%	196	24.0	12.2%
Average price⁵ per pack (PLN)											
Total ¹	22.0	22.0	22.0	0.07	0.3%	21.0	1.0	4.9%	20.9	1.1	5.1%
For reimbursed Rx products ²	29.2	28.9	28.5	0.6	2.3%	28.3	0.9	3.0%	28.1	0.8	2.8%
For nonreimbursed products ³	27.6	27.4	27.3	0.3	1.1%	26.0	1.6	6.0%	25.8	1.6	6.2%
For Non Rx products ⁴	17.2	17.2	17.1	0.0	0.1%	16.1	1.0	6.4%	16.2	0.9	5.8%
Average mark-up*											
Total ¹	25.1%	24.92%	24.7%	0.4%	1.5%	24.9%	0.2%	0.9%	24.9%	0.1%	0.3%
For reimbursed Rx products ²	19%	18.9%	18.8%	0.3%	1.7%	18.3%	0.8%	4.5%	18.7%	0.2%	1.2%
For nonreimbursed Rx products ³	22%	21.4%	20.8%	1.2%	5.6%	20.0%	2.0%	10.0%	20.4%	1.0%	5.1%
For Non Rx products ⁴	29%	29.2%	29.1%	0.2%	0.8%	31.0%	-1.6%	-5.2%	29.9%	-0.7%	-2.3%
Number of patients											
Total ¹	4 310	8 670	4 360	-50	-1.1%	3 890	420	10.8%	8 090	580	7.2%
For reimbursed Rx products ²	950	1 930	980	-30	-3.1%	770	180	23.4%	1 580	350	22.2%
For nonreimbursed Rx products ³	870	1 760	890	-20	-2.2%	780	90	11.5%	1 600	160	10.0%
For Non Rx products ⁴	3 530	7 070	3 540	-10	-0.3%	3 270	260	8.0%	6 810	260	3.8%
Number of pharmacies - summary[#]											
	13 710	13 738	13 765	-55	-0.4%	14 344	-634	-4.4%	14 396	-658	-4.6%

*Values in „Change – value“ for average mark-up in percentage points

[#] Number of pharmacies based on PEX's analysis.


- Pharmacies on the open market -



PEX PharmaSequence monthly report - February 2020

Price

- Structure of the average retail price⁵ -



All amounts are retail open pharmacy sales in PLN

Most important terms:

¹ Total open pharmacy market sales

² Total sales of Rx products covered by NHF reimbursement

³ Total sales of Rx products not covered by NHF reimbursement

⁴ Total sales of products available without prescription, including OTC medicines, food supplements, herbs, patches, medical devices, etc.

⁵ The calculation of the average price is based on products categorized and included in the pharmacy data database operated by PEX PharmaSequence and Kamsoft (Omnibus) – they make up 97% of the pharmacy market.

PEX PharmaSequence monthly report - February 2020

PEX PharmaSequence commentary

The pharmacy market in February 2020 saw sales go close to 3 348.1m PLN. Value of sales compared to February 2019 grew by over 296.0m PLN (+9.7%). Compared to January of 2020, sales fell by approximately 75.1m PLN (-2.2%).

Compared to the same period of 2019 the value of tracked segments grew for all monitored segments. Sales based on non-reimbursed prescriptions grew by 86.0m PLN (+13.1%), the non-prescription segment grew by 165.6m PLN (+12.2%), sales based on reimbursed prescriptions grew by 42.4m PLN (+4.2%).


Compared to the previous month, value of sales grew for one monitored segments. Value of reimbursed prescriptions fell by 48.2m PLN (-4.4%), value of non-reimbursed Rx drugs fell by 25.1m PLN (-3.3%) and value of products sold without a prescription grew by 4.7m PLN (+0.3%).

The average retail drug price in February 2020 was 22.0 PLN and was 0.3% higher than the average price in the previous month, and 4.9% higher than the average price in February 2019. The average retail price of reimbursed prescriptions was 29.2 PLN (+3.0% vs February 2019), 27.6 PLN for non-reimbursed prescriptions (+6.0% vs February 2019) and 17.2 PLN for products sold without a prescription (+6.4% vs February 2019).

Average pharmacy margin for all drugs in February 2020 was 25.1% and was higher by 0.9% than margin in the same period of 2019. Compared to January 2020, the average pharmacy margin was higher by 1.5%.

Drug reimbursement by the National Health Fund in February was in the amount almost 794m PLN, 5.1% more than in the same period of 2019. The level of patient copayment for reimbursed drugs in February was 23.7%, fell by 0.6p.p. compared to previous month.

- Monthly turnover value forecast (PLN million, retail gross prices) -




PEX PharmaSequence monthly report - February 2020

About us

PEX PharmaSequence is a Polish **consulting and research** company with its own wide-ranging resources of market data. We specialize in services for entities operating in the broadly defined healthcare market.

As a result of numerous projects, carried out over **almost 20 years** of the company's operations on the Polish market, for innovative, generic, and OTC producers, PEX PharmaSequence has gained unique expertise that allows us to provide our Clients with valuable support.



It is not without significance that our team, comprising **60+ people**, has the benefit of experience gained in service companies specializing in the pharma sector, as well as industry experience acquired in local and global pharmaceutical companies.

Our expertise and competencies as well as our **knowledge of the Polish pharma** market enable us to develop proposals and efficiently carry out projects, which offer added value to our Clients' business decisions.

We would like to hear from you!



www.pexps.pl more info



Ask us a question:
solutions_by_pex@pexps.pl
22 886 47 15

Published on the 23rd of March 2020, prepared by Marta Mazurek, Analyst based on PEX PharmaSequence data.

